Cargando…

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Background: Heart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rezar, Richard, Jirak, Peter, Gschwandtner, Martha, Derler, Rupert, Felder, Thomas K., Haslinger, Michael, Kopp, Kristen, Seelmaier, Clemens, Granitz, Christina, Hoppe, Uta C., Lichtenauer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019786/ https://www.ncbi.nlm.nih.gov/pubmed/31936148 http://dx.doi.org/10.3390/jcm9010164

Ejemplares similares

Mortality after cardiopulmonary resuscitation on a medical ICU: A sex-specific outcome analysis
por: Rezar, Richard, et al.
Publicado: (2021)

The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy
por: Topf, Albert, et al.
Publicado: (2020)

Hyperlactatemia and altered lactate kinetics are associated with excess mortality in sepsis: A multicenter retrospective observational study
por: Rezar, Richard, et al.
Publicado: (2022)

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study
por: Rezar, Richard, et al.
Publicado: (2021)

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
por: Jirak, Peter, et al.
Publicado: (2017)

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
por: Jirak, Peter, et al.
Publicado: (2020)

Partial oral antibiotic therapy is non-inferior to intravenous therapy in non-critically ill patients with infective endocarditis: Review and meta-analysis
por: Rezar, Richard, et al.
Publicado: (2020)

Heart Rate Variability and Cardiovascular Fitness: What We Know so Far
por: Souza, Hugo Celso Dutra, et al.
Publicado: (2021)

Understanding the preterm human heart: What do we know so far?
por: Schuermans, Art, et al.
Publicado: (2022)

Iron Deficiency in Heart Failure: What Do We Know So Far?
por: Elkammash, Amr, et al.
Publicado: (2022)

Overview of Current International Recommendations for Echocardiography Exams During the Covid-19 Pandemic and Its Local Implementation in Austria
por: Lichtenauer, Michael, et al.
Publicado: (2021)

MicroRNAs in Inflammatory Heart Diseases and Sepsis-Induced Cardiac Dysfunction: A Potential Scope for the Future?
por: Mirna, Moritz, et al.
Publicado: (2019)

What we know so far
Publicado: (2021)

Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021)

Management of intoxicated patients – a descriptive outcome analysis of 4,267 ICU patients
por: Rezar, Richard, et al.
Publicado: (2022)

Echokardiographieuntersuchungen in Zeiten der COVID-19-Pandemie: Internationale Empfehlungen und Umsetzung
por: Lichtenauer, Michael, et al.
Publicado: (2020)

Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021)

Incremental Hemodialysis: What We Know so Far
por: Soi, Vivek, et al.
Publicado: (2022)

Monkeypox transmission—what we know so far
por: Venkatesan, Priya
Publicado: (2022)

Amyloidogenesis: What Do We Know So Far?
por: Alraawi, Zeina, et al.
Publicado: (2022)

Moebius Syndrome: What We Know So Far
por: Zaidi, Syed Muhammad Hussain, et al.
Publicado: (2023)

Cell-Free Double-Stranded DNA to DNase Ratio Predicts Outcome after Primary Survived Cardiac Arrest
por: Rezar, Richard, et al.
Publicado: (2022)

COVID‐19 infection as a possible cause of complete heart block: What do we know so far?
por: Abobaker, Anis
Publicado: (2022)

The emotional attentional blink: what we know so far
por: McHugo, Maureen, et al.
Publicado: (2013)

Ketogenic Diet and Epilepsy: What We Know So Far
por: D’Andrea Meira, Isabella, et al.
Publicado: (2019)

Thunderstorm-triggered asthma: what we know so far
por: Harun, Nur-Shirin, et al.
Publicado: (2019)

Diet in the Treatment of Epilepsy: What We Know So Far
por: Verrotti, Alberto, et al.
Publicado: (2020)

Coronavirus advice for associates: what we know so far
por: Goldman, James
Publicado: (2020)

Smoking and COVID-19: What we know so far
por: Shastri, Madhur D., et al.
Publicado: (2021)

COVID-19 and cancer: what we know so far
por: Sidaway, Peter
Publicado: (2020)

Neuroproteomics in Epilepsy: What Do We Know so Far?
por: do Canto, Amanda M., et al.
Publicado: (2021)

Cholangiocarcinoma and liver transplantation: What we know so far?
por: Safarpour, Ali Reza, et al.
Publicado: (2021)

Carotid Artery Calcification: What We Know So Far
por: Ahmed, Madeeha, et al.
Publicado: (2021)

Update on omicron variant: What we know so far
por: Choudhary, Gajendra, et al.
Publicado: (2022)

COVID-19 and Myositis: What We Know So Far
por: Saud, Ahmad, et al.
Publicado: (2021)

Eosinophilic Esophagitis—What Do We Know So Far?
por: Wąsik, Jakub, et al.
Publicado: (2023)

HIV and neoplasms: What do we know so far?
por: de Souza, Thais Faria, et al.
Publicado: (2023)

Fibrocartilaginous dysplasia: What do we know so far?
por: Alshalan, Asma, et al.
Publicado: (2023)

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
por: Gschwandtner, Martha, et al.
Publicado: (2019)

Assessment of Cardiac Remodeling—A Chance for Novel Cardiac Biomarkers?
por: Jirak, Peter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4aup28jpqbh0m3lttlrisc12cg